Volpara Health Technologies Limited (ASX:VHT) shareholders have seen the share price descend 12% over the month. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 160% in that time. To some, the recent share price pullback wouldn’t be surprising after such a good run. Only time will tell if there is still too much optimism currently reflected in the share price.
Check out our latest analysis for Volpara Health Technologies
Given that Volpara Health Technologies didn’t make a profit in the last twelve months, we’ll focus on revenue growth to form a quick view of its business development. When a company doesn’t make profits, we’d generally expect to see good revenue growth. That’s because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last 3 years Volpara Health Technologies saw its revenue grow at 67% per year. That’s much better than most loss-making companies. Meanwhile, the share price performance has been pretty solid at 38% compound over three years. This suggests the market has recognized the progress the business has made, at least to a significant degree. Nonetheless, we’d say Volpara Health Technologies is still worth investigating – successful businesses can often keep growing for long periods.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
We’re pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. You can see what analysts are predicting for Volpara Health Technologies in this interactive graph of future profit estimates.
A Different Perspective
The last twelve months weren’t great for Volpara Health Technologies shares, which performed worse than the market, costing holders 17%. Meanwhile, the broader market slid about 8.8%, likely weighing on the stock. Fortunately the longer term story is brighter, with total returns averaging about 38% per year over three years. The recent sell-off could be an opportunity if the business remains sound, so it may be worth checking the fundamental data for signs of a long-term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we’ve spotted 3 warning signs for Volpara Health Technologies you should know about.
If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]wallst.com.